Dr. Giedrius Kalesnykas is Founder and Chief Executive Officer of Experimentica Ltd., a preclinical contract research organization specialized in ophthalmic models. He earned his Ph.D. in Neuroscience in 2005 from the University of Kuopio, Finland, and completed several postdoctoral fellowships studying the pathophysiology of glaucoma and ocular gene therapy. In 2009, Dr. Kalesnykas was awarded the prestigious position of Finnish Academy Research Fellow, which he held until 2013. He was a visiting researcher at the Wilmer Eye Institute at The Johns Hopkins University from 2010-2011. In 2013, he founded Experimentica Ltd., which under his leadership has grown to become one of the leading preclinical CROs dedicated to drug discovery and development for ophthalmic disorders.